Connexus Brain-Computer Interface for ALS

(CONNECT-ONE Trial)

This trial tests a device called the Connexus Brain-Computer Interface (BCI), designed to assist individuals who struggle to move or speak due to conditions like ALS. The device may enable users to communicate or control a computer using their thoughts. Individuals who have difficulty speaking, use a wheelchair, and have limited arm use might be suitable candidates. Participants must have a way to communicate and live within a 4-hour drive of the study center. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could improve communication for those with severe physical limitations.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

Research has shown that brain-computer interfaces (BCIs) can assist people with amyotrophic lateral sclerosis (ALS) in communicating, even with very limited muscle movement. The Connexus Brain-Computer Interface is currently undergoing testing to determine its safety. This study is an "early feasibility study," marking one of the initial steps to assess how well participants can tolerate the device.

Although specific safety data from past studies on the Connexus BCI is not available, other BCIs have demonstrated benefits without major safety issues. As this trial is in its early stages, detailed safety information remains limited. However, as an "early feasibility study," researchers are actively collecting initial safety data. Some unknowns may exist, but the primary goal is to ensure the device's safety for participants.

Researchers are excited about the Connexus Brain-Computer Interface for ALS because it offers a novel approach to managing the condition. Unlike traditional treatments that focus on slowing disease progression or managing symptoms, the Connexus system allows individuals with ALS to communicate and interact with their environment using brain signals. This brain-computer interface translates neural activity directly into commands, offering new possibilities for improved quality of life and independence for patients. This innovative technology opens the door to a future where physical limitations might not be as constraining.

Research has shown that the Connexus Brain-Computer Interface (BCI), which participants in this trial will use, could benefit people with amyotrophic lateral sclerosis (ALS). In one study, patients using similar BCIs achieved over 70% accuracy in tasks, sufficient for basic communication. Another study found that ALS patients completed 96.67% of tasks successfully using the BCI. These results suggest that Connexus BCI could help people with severe movement difficulties communicate better. Some ALS patients have even used the interface daily to operate computers independently. These findings highlight the potential of the Connexus BCI to improve communication for ALS patients.¹³⁴⁵⁶